

Table 1. Evaluation of antitoxoplasma antibodies.

Antibodies	ELISA		Feldman dye test
	IgG	IgM	
pre-transplantation	189	negative	64 X
day 143	44	negative	16 X

IgG and IgM antibodies were quantified with use of an ELISA, titers are expressed in units per milliliter (IU/mL). A patient is considered seropositive if titers are over 10 IU/mL. Pre-transplant serologic status positive for IgG but negative for IgM indicated past toxoplasma infection. On day 143, IgG titers decreased and IgM were not still detectable, in spite of definite proof of infection of toxoplasma in multiple tissues. These findings may be a reflection of impaired cellular and humoral immunity after transplantation, and may also indicate serologic status is not an appropriate tool for early diagnosis. The Feldman dye test is a more sensitive and specific neutralization test in which the organisms are lysed in the presence of IgG antibody and complement. The patient is considered to have a chronic infection if titers are over 16 X. In case of acute infection, titers are normally over 1,024 X.

for the life of the host.⁵ In the latent infection, parasite-specific T-lymphocytes release high levels of gamma interferon, which is required to activate and synergize macrophages for toxoplasma activity.⁵ Therefore, delayed immune reconstitution after transplantation puts patients at risk of reactivation of latent infection. The precise kinetics of immune reconstitution after CD34⁺ cell-selected PBSCT are unknown, however, substantial T-lymphocyte defects and consequent increased incidence of opportunistic infection have been reported. In our case, it is likely that the combination of CD34⁺ cell-selected PBSCT and TBI regimen resulted in a further-delayed immune-cell reconstitution and rendered the patient susceptible to disseminated toxoplasmosis. Although more studies need to be done to improve the understanding of immunologic impairment responsible for toxoplasmosis reactivation, prophylactic therapy for toxoplasmosis could be beneficial for seropositive patients especially in cases of CD34⁺ positive selected transplantation with TBI regimen.

Minoru Nakane, * Kazuteru Ohashi, * Junya Tominaga, ° Hideki Akiyama, * Kiyoshi Hiruma, * Hisashi Sakamaki*

*Bone Marrow Transplantation Team; °Pathology Division, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan

Key words

CD34 selection; toxoplasmosis; adult T-cell leukemia/lymphoma.

Acknowledgments

We thank Dr. A. Makioka (Iikei University, Tokyo, Japan) for performing the dye test.

Correspondence

Dr. Kazuteru Ohashi, M.D., Hematology Division, Tokyo Metropolitan Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan.

Phone: international +81-3-38232101 – Fax: international +81-3-38241552 – E-mail: k.ohashi-k@komagome-hospital.bunkyo.tokyo.jp

References

1. Nakane M, Ohashi K, Sato Y, et al. Molecular remission in adult T cell leukemia after autologous CD34⁺ peripheral blood stem cell transplantation. *Bone Marrow Transplant* 1999; 24:219-21.
2. Derouin F, Gluckman E, Beauvais B, et al. Toxoplasma infection after human allogeneic bone marrow transplantation: clinical and serological study of 80 patients. *Bone Marrow Transplant* 1986; 1:67-73.
3. Derouin F, Devergie A, Auber P, et al. Toxoplasmosis in bone marrow-transplant recipients: report of seven cases and review. *Clin Infect Dis* 1992; 15:267-70.
4. Slavin MA, Meyers JD, Remington JS, Hackman RC. Toxoplasma gondii infection in marrow transplant recipients: a 20 year experience. *Bone Marrow Transplant* 1994; 13:549-57.
5. Dagher R, Lucas K. Toxoplasmosis in the patient with cancer. *Infect Med* 1996; 13:998-1000.

Frequency of Gilbert's syndrome associated with UGT1A1 (TA)₇ polymorphism in Southern Italy

We screened 685 subjects from Southern Italy for a promoter polymorphism of the UDP-glucuronosyltransferase (UGT1A1) gene tightly linked to Gilbert's syndrome (GS), consisting in the insertion of a TA repeat in the TATA box. The frequency of the polymorphism was 0.387 which is similar to the frequencies reported for other investigated populations of different ethnic backgrounds and is consistent with the antiquity of this polymorphism.

Sir,

Gilbert's syndrome (GS) is an inherited form of mild unconjugated hyperbilirubinemia, characterized by decreased bilirubin UDP-glucuronosyltransferase activity (UGT1A1). Serum bilirubin levels vary according to time, intercurrent illness or fasting.¹

The recent identification of the UGT1A1 locus, which encodes for a family of UGT1A1 isoforms, has provided tools for molecular studies and for the correct definition of inheritance pattern.² Although heterozygous missense mutations have been identified in patients with GS, the majority of cases are associated with a length polymorphism in the promoter region. As a matter of fact, an unusual TATA box exists in 2 different forms, A(TA)₆TAA and A(TA)₇TAA, due to the presence of six or seven TA repeats.³ The presence of this expanded element reduces the efficiency of transcription of the UGT1A1 gene.

The incidence of GS can be evaluated by analysis of the promoter polymorphism; however, it is clear that forms due to exon (1 to 5) mutations may be under-evaluated.

The precise incidence of GS is not known, mainly because this condition is difficult to diagnose. After the description of the association of the (TA)₇ with GS, some studies focused on the relationship between GS and inherited red cell defects (spherocytosis, G6PD deficiency, thalassemia) and neonatal jaundice.^{4,7}

The aim of our study was to establish the gene frequency of the TA repeat promoter polymorphism in a

Southern Italy population.

After being given informed consent we examined 685 subjects (300 males and 385 females) from Southern Italy. By means of polymerase chain reaction and gel electrophoresis the subjects were genotyped for the TA promoter polymorphism.⁴ The prevalence of homozygosity for the (TA)₇ allele was 15%. Table 1 reports the allele frequencies found in other studies and the present study.

In Caucasian people, the estimated gene frequency of (TA)₇ is 0.387. The frequency of the (TA)₇ promoter is lowest in Asian (0.16) and highest in African populations (0.426), where two other variants have been identified, (TA)₅ and (TA)₈, with relative frequencies of 0.035 and 0.069, respectively.⁸ Our data are in agreement with data reported by Beutler *et al.*⁷ concerning a Caucasian population. The allele frequency in an African population appears the same as that of non-Africans as well as the Sardinian population.^{4,7,8} These data are consistent with the oldness of the polymorphism, which appears to be homogeneously distributed in the world.

The result from the Asian population appears discordant; this could be due to the relative low number of subjects and to the relative heterogeneity of the examined population.^{8,9} It is noteworthy that a missense Gly71Arg mutation, associated with GS, is present in 19% of the population of Asian origin. Preliminary analysis on Caucasian chromosomes have demonstrated that this polymorphism is very rare (Iolascon *et al.*, unpublished data).

(TA)₇ polymorphism is strongly associated with higher bilirubin levels.

The very high prevalence of this polymorphism could be relevant in Mediterranean countries where there is a high incidence of inherited hemolytic diseases. The co-inheritance of GS with a hemolytic red cell defect could account for the heterogeneity of clinical findings (hyperbilirubinemia, gallstones) in affected kindred.¹⁰

Achille Iolascon, ° Silverio Perrotta, * Brigida Coppola, ° Ruggiero Carbone, ° Emanuele Miraglia del Giudice*

°Dipartimento di Biomedicina dell'Età Evolutiva, Università di Bari;

*Dipartimento di Pediatria, Seconda Università di Napoli, Italy

Key words

Gilbert's syndrome, hyperbilirubinemia, UGTA1, TA repeat.

Correspondence

A. Iolascon, M.D., Dipartimento di Biomedicina dell'Età Evolutiva, p.zza G. Cesare, 11, 70124 Bari, Italy. Phone: international +39-080-5478923 – Fax: international +39-080-5592290 – E-mail: a.iolascon@bioetaev.uniba.it

Table 1. UGTA1 allele frequencies.

Ref.	(TA) ₆	(TA) ₇	n° of subjects
Iolascon	43	57	685 (Italy)
Bancroft (9)	37	63	151 (USA)
Kaplan (5)	37	63	240 (Sephardic J.)
Beutler (7)	38	62	71 (Europe)
Beutler (7)	42	47	101 (Africa)
Beutler (7)	16	84	47 (Asia)
Akaba (8)	7	93	159 (Japan)
Galanello (4)	40	60	70 (Sardinia)

References

1. Sampietro M, Iolascon A. Molecular pathology of Crigler-Najjar type I and II and Gilbert's syndromes. *Haematologica* 1999; 84:150-7.
2. Ritter JK, Chen F, Sheene YY, et al. A novel complex locus UGT1 encodes human bilirubin, phenol, and others UDP-glucuronosyltransferase isozymes with identical carboxyl termini. *J Biol Chem* 1992; 267: 3257-61.
3. Monaghan G, Ryan M, Seddon R, Hume R, Burchell B. Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome. *Lancet* 1996; 347:578-81.
4. Galanello R, Perseu L, Melis MA, et al. Hyperbilirubinemia in heterozygous β -thalassaemia is related to co-inherited Gilbert's syndrome. *Br J Haematol* 1997; 99:433-6.
5. Kaplan M, Renbaum P, Levy-Lahad E, Hammerman C, Lahad A, Beutler E. Gilbert syndrome and glucose-6-phosphate dehydrogenase deficiency: A dose-dependent genetic interaction crucial to neonatal hyperbilirubinemia. *Proc Natl Acad Sci USA* 1997; 94:12128-32.
6. Iolascon A, Faienza MF, Moretti A, Perrotta S, Miraglia del Giudice E. UGT1 promoter polymorphism accounts for increased neonatal appearance of hereditary spherocytosis. *Blood* 1998; 91:1093.
7. Bancroft JD, Kreamer B, Gourley GR. Gilbert syndrome accelerates development of neonatal jaundice. *J Pediatr* 1998; 132:656-60.
8. Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? *Proc Natl Acad Sci USA* 1998; 95:8170-4.
9. Akaba K, Kimura T, Sasaki A, et al. Neonatal hyperbilirubinemia and a common mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene in Japanese. *J Hum Genet* 1999; 44:22-5.
10. Galanello R, Cipollina MD, Dessi C, Giagu N, Lai E, Cao A. Co-inherited Gilbert's syndrome: a factor determining hyperbilirubinemia in homozygous beta-thalassaemia. *Haematologica* 1999; 84:103-5.